Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $-11.29M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Gilead Sciences USD 2.96B 551M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Merck USD 6.24B 318M Dec/2025